1203 related articles for article (PubMed ID: 21540550)
21. Combinatorial CAR design improves target restriction.
Köksal H; Dillard P; Juzeniene A; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
J Biol Chem; 2021; 296():100116. PubMed ID: 33234592
[TBL] [Abstract][Full Text] [Related]
22. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.
Cappell KM; Kochenderfer JN
Nat Rev Clin Oncol; 2021 Nov; 18(11):715-727. PubMed ID: 34230645
[TBL] [Abstract][Full Text] [Related]
23. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.
Kebriaei P; Huls H; Jena B; Munsell M; Jackson R; Lee DA; Hackett PB; Rondon G; Shpall E; Champlin RE; Cooper LJ
Hum Gene Ther; 2012 May; 23(5):444-50. PubMed ID: 22107246
[TBL] [Abstract][Full Text] [Related]
24. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
25. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
Front Immunol; 2022; 13():836549. PubMed ID: 35222427
[TBL] [Abstract][Full Text] [Related]
26. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
Hombach AA; Rappl G; Abken H
Mol Ther; 2013 Dec; 21(12):2268-77. PubMed ID: 23985696
[TBL] [Abstract][Full Text] [Related]
27. T cells redirected against Igβ for the immunotherapy of B cell lymphoma.
Jiang D; Tian X; Bian X; Zhu T; Qin H; Zhang R; Xu Y; Pan Z; Huang H; Fu J; Wu D; Chu J
Leukemia; 2020 Mar; 34(3):821-830. PubMed ID: 31624374
[TBL] [Abstract][Full Text] [Related]
28. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
[TBL] [Abstract][Full Text] [Related]
29. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
30. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors.
Muliaditan T; Halim L; Whilding LM; Draper B; Achkova DY; Kausar F; Glover M; Bechman N; Arulappu A; Sanchez J; Flaherty KR; Obajdin J; Grigoriadis K; Antoine P; Larcombe-Young D; Hull CM; Buus R; Gordon P; Grigoriadis A; Davies DM; Schurich A; Maher J
Cell Rep Med; 2021 Dec; 2(12):100457. PubMed ID: 35028604
[TBL] [Abstract][Full Text] [Related]
31. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
32. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
[No Abstract] [Full Text] [Related]
33. CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells.
Velasquez MP; Szoor A; Vaidya A; Thakkar A; Nguyen P; Wu MF; Liu H; Gottschalk S
Cancer Immunol Res; 2017 Oct; 5(10):860-870. PubMed ID: 28821531
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
[TBL] [Abstract][Full Text] [Related]
35. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
[TBL] [Abstract][Full Text] [Related]
36. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
[TBL] [Abstract][Full Text] [Related]
37. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
[TBL] [Abstract][Full Text] [Related]
38. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
[TBL] [Abstract][Full Text] [Related]
39. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
[TBL] [Abstract][Full Text] [Related]
40. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA; Abken H
Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
